Hypercholesterolemia Drugs Market By Drugs Class (Top 3 Countries, HMG-CoA Reductase Inhibitors/ Statins, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors) - Growth, Future Prospects, And Competitive Analysis, 2017 - 2025

Factors such as an increase in awareness of hypercholesterolemia and cardiovascular diseases, changing lifestyle patterns, an increase in the number of obese people, and a growing geriatric population are driving the growth of the hypercholesterolemia drugs market globally.

The report titled "Hypercholesterolemia Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall hypercholesterolemia drugs market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug class and different geographical regions.

Geographically, the global hypercholesterolemia drugs market is studied for the following regional markets:

North America

  • U.S.
  • Canada


  • U.K.
  • Germany
  • Rest of Europe


  • China
  • Japan
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of LATAM

Middle East and Africa

  • GCC
  • the remainder of MEA

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global hypercholesterolemia drugs market.

Tools such as market positioning of key players, pipeline analysis, and an appealing investment proposition provide readers with insights into the global hypercholesterolemia drugs market's competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global hypercholesterolemia drugs market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global hypercholesterolemia drugs market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on drug class, the global hypercholesterolemia drugs market is segmented as follows:

  • Statins/HMG-CoA Reductase Inhibitors
  • Bile acid sequestrants
  • Fibrates
  • Inhibitors of Cholesterol Absorption
  • Others

Hypercholesterolemia, also known as high cholesterol, is characterized by the presence of high levels of cholesterol in the body, which increases the risk of developing a heart attack or stroke. Some factors such as changing lifestyle patterns, rising healthcare awareness, an increase in the number of obese people, the growing incidence of hypercholesterolemia-related diseases, growing awareness about cardiovascular diseases, and a rising geriatric population are primarily driving the growth of the hypercholesterolemia drugs market globally.

For the purpose of the study, the hypercholesterolemia drugs market is segmented on the basis of drug class, such as HMG-CoA reductase inhibitors, bile acid sequestrants, fabric acid derivatives, cholesterol absorption inhibitors, and others. It has been determined that, among the market segments considered, statins are a significant revenue contributor because they are recommended for use in the management of hypercholesterolemia due to their safety and effectiveness. Furthermore, statins completely inhibit HMG-CoA reductase, which is responsible for cholesterol production; additionally, statins are involved in decreasing LDL cholesterol levels and increasing HDL cholesterol levels and are thus most preferred in the hypercholesterolemia market.

For the purpose of this study, the hypercholesterolemia drugs market is categorized into three categories:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Among the considered market segments, North America dominated the global hypercholesterolemia market, and growth was primarily driven by the United States. Some factors, such as sedentary lifestyle patterns, higher cost of medication, a large number of target populations, increasing risk of cardiovascular diseases, and higher treatment awareness, are prime factors that are assisting the market's growth in North America.

According to the Centers for Disease Control and Prevention (CDC), more than 73.5 million adults (31.7%) in the United States have high low-density lipoprotein. Nearly 31 million adult Americans, have a total cholesterol level greater than 240 mg/dL. According to the World Health Organization (WHO), more than half of adults in high-income countries had elevated total cholesterol, which was more than twice the level in low-income countries. It is estimated that Asia Pacific will show the highest growth during the forecast period due to rising healthcare awareness and changing lifestyle patterns that will influence the market growth of hypercholesterolemia drugs.

Frequently Asked Question:

The market for Hypercholesterolemia Drugs Market is expected to reach USD$ XX MN in 2025.

The Hypercholesterolemia Drugs Market is expected to see significant CAGR growth over the coming years, at 5.6%.

The base year of this report is 2016.

The base year of this report is 2016.

AbbVie Inc.,Aegerion Pharmaceuticals,Amgen Inc.,AstraZeneca,Eli Lilly and Company. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Sep 2017
Category:  Pharmaceuticals
Report ID:   58670
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support